Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status

Shanghai 10th People's Hospital20 enrolled

Overview

GLP-1 receptor agonists promote fat redistribution in obese women with type 2 diabetes, reduce liver fat content, improve the inflammation state

As a treatment for type 2 diabetesGlucagon like peptide -1 (Glucan-like peptide-1, GLP-1) receptor agonists plays the role of promoting insulin secretion, inhibiting glucagon secretion，and also has the central and peripheral effects,it can inhibit appetite,reduce weight.GLP-1 receptor agonists promote fat redistribution in obese women with type 2 diabetes, reduce liver fat content, improve the inflammation state

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Obesity

Interventions

ExenatideDRUG

5ug bid,Subcutaneous injection

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of overweight and type 2 diabetes mellitus Exclusion Criteria: * Poor body condition (severe liver and kidney dysfunction) * Unknown causes of pancreatitis, chronic pancreatitis, pancreatic resection, stomach operation, malignant tumor, previous use of systemic corticosteroids (local or inhalation of exceptions) heart function or niacin, incomplete * serious endocrine disease * genetic disease

Locations (1)

Shanghai Tenth People' Hospital

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Dual energy X-ray absorptiometry

fat distribution

Time frame: 3 month

Secondary Outcomes

lab testing

inflammation

Time frame: 3 month

Central Contacts

Yu Jie

CONTACT

13916674766

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.